A comparative study of ferric citrate in patients of cardio renal anemia syndrome.

Avinash Chaudhari; Amar Kulkarni; Mehak Trikha; Dinesh Gupta

Volume : IX, Issue : I, January - 2020

A comparative study of ferric citrate in patients of cardio renal anemia syndrome.

Avinash Chaudhari, Amar Kulkarni, Mehak Trikha, Dinesh Gupta

Abstract :

INTRODUCTION: The Cardio Renal Anemia syndrome is a process involving the deterioration of heart and kidney function linked with worsening anemia. Hyperphosphatemia is crucial indicator of poor prognosis in cardio renal anemia syndrome. Ferric citrate has proven to be effective in reducing serum phosphorus and increasing iron stores and hemoglobin in individuals with non-dialysis-dependent CKD who have iron-deficiency anemia. MATERIALS AND METHODS: After the approval of EC, this prospective study was conducted in D.Y Patil Hospital Navi Mumbai. 50 patients were enrolled in the study and randomized into two treatment groups- one group receiving oral ferric citrate and other ferrous fumarate. RESULTS: Out of 50 patients, 18 (36%) were females and 32 (64%) were male. Most common sub type of CRAS was type 2 comprising of 25 patients (50%). The rise in mean biochemical parameters in ferric citrate group at week 52 were statistically significant as compared to baseline. Serum phosphate levels were reduced towards normal level in ferric citrate group at week 52, as compared to in ferrous fumarate group at same time point in the study(p<0.05). CONCLUSION:.The present study has shown ferric citrate to be superior to ferric fumarate in improving the hemoglobin, iron, RBC indices and as a phosphate binder in patients with CRAS.